ABSTRACT

Introduction: Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus and the leading cause of blindness in young adults. Prior to anti-vascular endothelial growth factor (anti-VEGF) agents, the treatment of DR was based on control of systemic factors and laser photocoagulation. Over the past decade, the use of anti-VEGF agents has revolutionized the treatment of DR, including diabetic macular edema (DME).

Areas covered: Ranibizumab has been proven to be effective for the treatment of DME in large clinical trials, while patients in these studies have been assessed in terms of DR severity change. In this review, evidence from randomized trials regarding the use of ranibizumab for DR treatment is presented.

Expert opinion: A comprehensive presentation of randomized clinical trials evaluating ranibizumab for DR indicates that it is effective and safe, offering improvement of DR severity in both non-proliferative and proliferative forms. However, there is no general consensus regarding the exact treatment regimen in patients with DR, while the effect of ranibizumab on the progression of retinal ischemia remains unclear.

摘要

简介：糖尿病视网膜病变（DR）是糖尿病最常见的微血管并发症，也是导致年轻人失明的主要原因。在抗血管内皮生长因子 (anti-VEGF) 药物出现之前，DR 的治疗基于对全身因素的控制和激光光凝术。在过去的十年中，抗 VEGF 药物的使用彻底改变了 DR 的治疗，包括糖尿病性黄斑水肿 (DME)。

涵盖的领域：雷珠单抗已在大型临床试验中被证明对治疗 DME 有效，而这些研究中的患者已根据 DR 严重程度变化进行了评估。在这篇综述中，提供了关于使用雷珠单抗治疗 DR 的随机试验证据。

专家意见：评估雷珠单抗治疗 DR 的随机临床试验的综合报告表明它是有效和安全的，可改善非增殖和增殖形式的 DR 严重程度。然而，对于 DR 患者的确切治疗方案尚无普遍共识，而雷珠单抗对视网膜缺血进展的影响仍不清楚。